Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cost of Revenue (2022 - 2024)

Amylyx Pharmaceuticals (AMLX) has 3 years of Cost of Revenue data on record, last reported at $8000.0 in Q2 2024.

  • For Q2 2024, Cost of Revenue fell 99.86% year-over-year to $8000.0; the TTM value through Mar 2025 reached $8000.0, down 99.97%, while the annual FY2024 figure was $6.0 million, 76.6% down from the prior year.
  • Cost of Revenue reached $8000.0 in Q2 2024 per AMLX's latest filing, down from $5.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $9.4 million in Q4 2023 and bottomed at $8000.0 in Q2 2024.
  • Average Cost of Revenue over 3 years is $4.3 million, with a median of $5.3 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: soared 2933.72% in 2023, then tumbled 99.86% in 2024.
  • A 3-year view of Cost of Revenue shows it stood at $2.8 million in 2022, then soared by 231.8% to $9.4 million in 2023, then plummeted by 99.91% to $8000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $8000.0 in Q2 2024, $5.9 million in Q1 2024, and $9.4 million in Q4 2023.